C07D 513/20
Spiro-condensed systems
C07D513/20 (Spiro-condensed systems) appears on 53 US grants and 77 published applications in this corpus.
Search patents in C07D- Granted patents
- 53
- Published applications
- 77
- Assignees
- 53
- Inventors
- 420
- Latest grant
- 2 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 1 | 0 |
| 2008 | 1 | 3 |
| 2009 | 0 | 1 |
| 2010 | 0 | 2 |
| 2011 | 1 | 5 |
| 2012 | 1 | 4 |
| 2013 | 6 | 1 |
| 2014 | 3 | 9 |
| 2015 | 5 | 3 |
| 2016 | 6 | 4 |
| 2017 | 6 | 4 |
| 2018 | 1 | 0 |
| 2019 | 0 | 1 |
| 2020 | 1 | 4 |
| 2021 | 3 | 4 |
| 2022 | 3 | 2 |
| 2023 | 5 | 11 |
| 2024 | 2 | 8 |
| 2025 | 4 | 4 |
| 2026 | 0 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof2 Dec 2025US 12,486,289 B2Biogen MA Inc.
- Spiro compound serving as ERK inhibitor, and application thereof26 Aug 2025US 12,398,153 B2D3 Bio (Wuxi) Co., Ltd.
- NMDA receptor modulators and uses thereof15 Jul 2025US 12,358,929 B2Novartis AG
- MCL1 inhibitors21 Jan 2025US 12,202,842 B2Gilead Sciences, Inc.
- Spirotricycle RIPK1 inhibitors and methods of uses thereof31 Dec 2024US 12,180,226 B2Merck Sharp & Dohme Corp.
- Compounds as sumo activating enzyme inhibitors1 Oct 2026US 2026/0297109 A1Wigen Biomedicine Technology (Shanghai) Co., Ltd.
- Ras inhibitors1 Oct 2026US 2026/0297112 A1Revolution Medicines, Inc.
- Compounds comprising heteroaryl rings and compositions and methods thereof30 Jul 2026US 2026/0217697 A1lonGen Therapeutics Co., Ltd.
- Ras inhibitors19 Mar 2026US 2026/0078133 A1Revolution Medicines, Inc.
- Compounds as sumo activating enzyme inhibitors5 Feb 2026US 2026/0035382 A1Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Most cited
By later US patents
- Modulation of chemosensory receptors and ligands associated therewith66US 8,633,186 B2Senomyx, Inc. · 2014
- Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors54US 7,928,111 B2Senomyx, Inc. · 2011
- Bromodomain inhibitors and uses thereof50US 9,249,161 B2Constellation Pharmaceuticals, Inc. · 2016
- Process for the manufacture of spiro-linked pyrrolidine-2,5-dione derivatives33US 4,764,608 AKyorin Pharmaceutical Co., Ltd. · 1988
- Methods of enhancing sweet taste of compositions using substituted thieno{2,3-D}pyrimidines33US 8,541,421 B2Senomyx, Inc. · 2013